Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.71B
Enterprise ValueAU$2.27B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding597,559,140
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$29.50M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Imaging Tech4DMedical’s XV CT-based lung ventilation analytics is a proprietary clinical platform sold to healthcare providers. This differentiated technology creates clinical integration barriers and recurring use potential, supporting durable adoption and specialty-market positioning over time.
Conservative LeverageLow debt-to-equity and conservative leverage reduce insolvency and financing pressure, preserving strategic optionality. This financial conservatism supports continued investment in clinical trials, regulatory work, and commercialization without immediate refinancing risk.
High Gross MarginsReported high gross profit margins indicate favorable unit economics in imaging/software delivery. If revenue scale improves, these margins provide a clear route to operating leverage and sustainable cash generation from recurring software or service contracts.
Bears Say
Declining RevenueA shrinking top line (-6.1%) signals weakening commercial traction and slows the path to scale. Prolonged revenue contraction reduces ability to absorb fixed costs, lengthens time to profitability, and undermines returns on product development and sales investments.
Negative Cash FlowNegative operating and free cash flows reflect ongoing cash burn that erodes runway. Persistent cash deficits force reliance on external funding, increasing dilution and constraining necessary R&D, regulatory and commercial spend to sustain long-term growth.
Persistent UnprofitabilityNegative net and EBIT margins and negative ROE show continued unprofitability. This limits internal reinvestment capacity, raises financing risk, and increases execution pressure to achieve clinical adoption and regulatory milestones required for durable profitability.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.71B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 57 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 597,559,140 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$4.97 (-14.95% Downside)
AU$4.97 (-14.95% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 94%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$100.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.97
▼(-14.95% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---